- Sarepta Therapeutics (SRPT) is up ~10% in after-hours trading Friday after announcing it will release topline, 3-year results from its EMBARK study of Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy the morning of Jan. 26.
- The data from part 1 is in ambulatory patients with Duchenne who were four to seven years old at time of treatment.
- The company will hold a webcast and conference call at 830a ET on Jan. 26.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.